,trastuzumab deruxtecan
daiichi sankyo,astrazeneca
[]
amazing #asco22 plenary session so far! especially db-04 trial results! #asco22 #db-04 
IM Resident @ECUIMchiefs. Aspiring Hematology/Oncologist #WomenInMedicine